Gilead Sciences, Inc., is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping people with hard-to-treat cancers. Our proprietary ADC binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. For more information, visit: www.gilead.com.
Featured Content
